RxDoctor Payments Data

Elaine Young, MD

Dermatology · Huntington, WVNPI 1376528356

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $809 of the $904 with a category attached, or 89.5%. 6 manufacturers reported payments, led by Johnson & Johnson at 44.0% of the total. Reporting peaked in 2023 at $276 and has fallen 94.3% since, to $16 in 2025. That places this record below the midpoint for dermatology clinicians in WV, where the typical reported total is $2,210.

$904in general payments, 2019–2025

Across 54 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$398
  • AbbVie$172
  • Pfizer$141
  • Janssen Scientific Affairs, LLC$125
  • Incyte Corporation$52
  • Novartis$17

What the payments were for

  • Food & beverage$80989%
  • Education$9511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904 in reported general payments places this provider in the 35th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$157,952
Medicare patients
639
Services billed
2,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab67$281,108
Skyrizi PenRisankizumab-Rzaa13$270,452
Humira(Cf) PenAdalimumab36$255,111
StelaraUstekinumab12$216,299
Taltz AutoinjectorIxekizumab12$85,063
Dupixent SyringeDupilumab21$75,618
OpzeluraRuxolitinib Phosphate20$40,410
Acitretin31$7,075
Fluorouracil87$5,809
Clobetasol Propionate60$5,360
Metronidazole105$5,125
Doxycycline Hyclate114$3,955
Ketoconazole189$3,676
Imiquimod187$3,443
Tretinoin66$3,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$398$216,29912 claims
Incyte CorporationOpzelura$52$40,41020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 39 dermatology providers in West Virginia.

Other dermatology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →